ID   WIL2 S
AC   CVCL_3809
SY   WIL2-S; WIL2/S; WIL2S; WIL2 Secreting
DR   BTO; BTO:0001525
DR   CLO; CLO_0009605
DR   AddexBio; C0003018/4890
DR   ATCC; CRL-8885
DR   CCRID; 1102HUM-NIFDC00032
DR   Cell_Model_Passport; SIDM01075
DR   Lonza; 966
DR   Wikidata; Q54994066
RX   Patent=US4806476;
CC   Group: Hybridoma fusion partner cell line.
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8885.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Derived from site: In situ; Spleen; UBERON=UBERON_0002106.
ST   Source(s): AddexBio; ATCC
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 11
ST   D16S539: 11,12
ST   D5S818: 12,13
ST   D7S820: 9,11
ST   F13A01: 6,7
ST   F13B: 10
ST   FESFPS: 11,12
ST   LPL: 9,10
ST   TH01: 8,9.3
ST   TPOX: 8,11
ST   vWA: 17,20
DI   NCIt; C97074; Hereditary spherocytosis
DI   ORDO; Orphanet_822; Hereditary spherocytosis
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_6544 ! WIL2
SX   Male
AG   5Y
CA   Transformed cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 23
//
RX   Patent=US4806476;
RA   Coons T., Avner B.;
RT   "Efficient cell fusion process.";
RL   Patent number US4806476, 21-Feb-1989.
//